ALPMY - Astellas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
http://www.astellas.com

SectorHealthcare
IndustryDrug Manufacturers—General
Full Time Employees16,243

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenji Yasukawa Ph.D.Pres, CEO & Representative DirectorN/AN/A1960
Mr. Naoki OkamuraChief Strategy Officer, CFO, Corp. Exec. VP & Representative DirectorN/AN/AN/A
Mr. Fumiaki SakuraiChief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.N/AN/AN/A
Ms. Linda FriedmanGen. Counsel & VPN/AN/AN/A
Mr. Stig OgataVP of Corp. CommunicationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Corporate Governance

Astellas Pharma Inc.’s ISS Governance QualityScore as of October 4, 2019 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 6; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.